ArticleBiomedicines2021
Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy.
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study.BMC pulmonary medicine · 2026Article
- Choosing and switching biologics for patients with severe asthma: Real-world data from the German Asthma Net (GAN).Allergologie select · 2026Article
- Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study.BMC pulmonary medicine · 2025Article
- Factors influencing the real-world effectiveness of benralizumab in uncontrolled asthma.Scientific reports · 2025Observational
- Advancing Care in Severe Asthma: The Art of Switching Biologics.Advances in respiratory medicine · 2024Review
- Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.Journal of asthma and allergy · 2024Article
- Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period.Journal of asthma and allergy · 2024Article
- Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study.Journal of clinical medicine · 2023Article
- Switching Biological Therapies in Severe Asthma.International journal of molecular sciences · 2023Review
- Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis.Journal of clinical medicine · 2023Review
- Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.Frontiers in immunology · 2023Observational
- Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2023Article
- Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study.ERJ open research · 2022Article
- Novel Biological Therapies for Severe Asthma Endotypes.Biomedicines · 2022Review
- Local and Systemic Production of Pro-Inflammatory Eicosanoids Is Inversely Related to Sensitization to Aeroallergens in Patients with Aspirin-Exacerbated Respiratory Disease.Journal of personalized medicine · 2022Article
- Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE studyFrontiers in medicine · 2022Article
- Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma.Journal of asthma and allergy · 2022Article
- Biological therapy for severe asthma - Indian perspectives and challenges.Lung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe wide availability of monoclonal antibodies for the add-on therapy of severe asthma currently allows for the personalization of biologic treatment by selecting the most appropriate drug for each patient. However, subjects with overlapping allergic and eosinophilic phenotypes can be often eligible to more than one biologic, so that the first pharmacologic choice can be quite challenging for clinicians. Within such a context, the aim of our real-life investigation was to verify whether allergic patients with severe eosinophilic asthma, not adequately controlled by an initial biologic treatment with omalizumab, could experience better therapeutic results from a pharmacologic shift to benralizumab. PATIENTS AND
methodsTwenty allergic patients with severe eosinophilic asthma, unsuccessfully treated with omalizumab and then switched to benralizumab, were assessed for at least 1 year in order to detect eventual changes in disease exacerbations, symptom control, oral corticosteroid intake, lung function, and blood eosinophils.
resultsIn comparison to the previous omalizumab therapy, after 1 year of treatment with benralizumab our patients experienced significant improvements in asthma exacerbation rate (
conclusionThe results of this real-life study suggest that the pharmacologic shift from omalizumab to benralizumab can be a valuable therapeutic approach for allergic patients with severe eosinophilic asthma, not adequately controlled by anti-IgE treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.